ABSTRACT The effect of flurbiprofen, a potent cyclo-oxygenase inhibitor, on histamine and methacholine reactivity was assessed in seven atopic subjects with asthma. Flurbiprofen 150 mg daily for three days displaced the histamine-FEV, concentration-response curve to the right by 1.5 doubling doses, whereas no effect was observed on the response to methacholine. Subsequently the effects of flurbiprofen and terfenadine, a specific H, histamine receptor antagonist, on allergen induced bronchoconstriction were studied in seven atopic but non-asthmatic subjects. The subjects inhaled the concentration of grass pollen allergen that had previously been shown to produce a 20% fall in FEV, on separate occasions after prior treatment with placebo, flurbiprofen 150 mg daily for three days, terfenadine 180 mg three hours before challenge, and the combination of flurbiprofen and terfenadine. After placebo, allergen challenge caused a mean (SEM) maximum fall in FEV, of 37-6% (2 6%) after 20 (3 7) minutes, followed by a gradual recovery to within 1 5 % of baseline at 60 minutes. Terfenadine reduced the maximum allergen provoked fall in FEV, to 21-5% (2-2%) and reduced the area under the time-response curve (AUC) by 50% (6%). Flurbiprofen alone reduced the mean maximum fall in FEV, to 29-6% (3-2%) and reduced the AUC by 26%. The effect of the combination of flurbiprofen and terfenadine did not differ significantly from that of terfenadine alone. We conclude that histamine and prostaglandins contribute to immediate allergen induced bronchoconstriction and that a complex interaction occurs between the two classes of mediators.
Introduction
In individuals with atopic asthma the magnitude ofthe airway response to inhaled allergen is a function of mediator release and non-specific bronchial responsiveness.' In subjects with mild asthma allergen provocation sufficient to cause bronchoconstriction is accompanied by release into the circulation of the mast cell associated mediators, histamine and high molecular weight neutrophil chemotactic factor,2 and the secondary mediators, 13,14-dihydro-15-ketoprostaglandin F2,,3 thromboxane B2,4 and platelet factor 4.5 Sodium cromoglycate inhibits allergen provoked bronchoconstriction' and attenuates the increase in circulating concentrations ofhistamine and neutrophil chemotactic factor,2 implying a role for the mast cell in mediating the response.
Immunoglobulin E dependent activation of mast cells dispersed from human lung tissue7 or obtained by bronchoalveolar lavage' releases both granule derived mediators and newly formed products from the cyclooxygenation and 5-lipoxygenation of arachidonic acid. Prostaglandin D2, the major cyclo-oxygenase product released from human mast cells,9 is a potent bronchoconstrictor in asthma.'" The contribution of individual mediators to allergen induced bronchoconstriction can be investigated by using specific pharmacological agents that inhibit synthesis of the mediator or specifically antagonise its effects on target tissues. In this study we have investigated the effect of Effects offlurbiprofen and terfenadine on allergen induced immediate bronchoconstriction terfenadine, a potent and highly selective H, histamine receptor antagonist, and flurbiprofen, a cyclo-oxygenase inhibitor at least 5000 times more potent than aspirin," on histamine and allergen induced bronchoconstriction and skin weal and flare responses in atopic subjects. Flurbiprofen and terfenadine were observed alone and in combination to examine the relative contributions ofhistamine and prostaglandins to the allergen response in the skin and airways.
Methods
The study was undertaken in two stages. Firstly, the influence of flurbiprofen on the airway response to histamine and methacholine was assessed in seven atopic patients with mild asthma. The subjects were aged 21-44 years and had a mean FEV, of 91-7% (SEM 7 2%) predicted, and their asthma was controlled with inhaled /2-adrenoreceptor agonists alone.
Since flurbiprofen was shown to reduce airway responsiveness to histamine in these subjects, a second study was carried out on seven atopic but non-asthmatic subjects (aged 21-25 years), none ofwhom had a 20% fall in FEV, after inhaling histamine at a concentration of 32 mg/ml. None of the subjects in either study was taking oral or inhaled corticosteroids, sodium cromoglycate, theophylline, or antihistamines, and none had a history ofanalgesia induced asthma, upper gastrointestinal ulceration, or dyspepsia. Both studies were approved by the Southampton Hospitals and University Ethical Committee, and informed consent was obtained from each subject. Each subject initially underwent an inhalation challenge test to determine the concentration of allergen required to provoke a 30% fall in FEV, nine minutes after challenge. Allergen solutions were prepared from a 6% stock solution of mixed grass pollen extract (group B2, Bencard, Brentford, Middlesex) to produce a range ofconcentrations from 10-6 to 10-' x 6 mg/ml. All solutions were nebulised from a starting volume of2 ml in an Inspiron nebuliser (CR Bard International, Pennywell Industrial Estate, Sunderland) driven by compressed air at 8 I/min-'. Allergen challenge was performed using a method modified from that described by Chai et al. FEV, was recorded before and two minutes after inhalation of nebulised 0 9% saline. If the FEV, after saline had not fallen by 10% from baseline, the PC30 concentration of allergen was administered and the FEV, recorded at regular intervals for one hour after challenge.
Histamine and allergen dose-response curves were also constructed for the skin at each visit, by means of intradermal injections ofhistamine acid phosphate (4-128 mg/ml) and six concentrations of grass pollen allergen (1_10-6 x 6 mg/ml). A standardised skinprick 948 procedure was used and the area of each weal was measured after 10 Skinprick tests with increasing concentrations of both histamine and allergen produced dose related skin weal responses, with a mean total weal area after allergen and after histamine of 2-58 (SEM 0 28) and 2-68 (0 27) cm2 respectively. Treatment with flurbiprofen increased the mean total weal area to histamine by 28% (NS) and to allergen by 36% (p < 0.01). Terfenadine, alone or in combination with flurbiprofen, substantially inhibited the weal response to both histamine and allergen. The mean total weal area to histamine was inhibited 94% (3%) (p < 0-01) by terfenadine alone and by 97% (2%) (p < 0-01) by the combination of terfenadine and flurbiprofen, the two values not differing significantly. Terfenadine alone reduced the mean total weal area for allergen by 62% (4%) (p < 0-01), which was not significantly different from that produced by the treatment combination (59% (4%)).
Discussion
This study has shown that in atopic non-asthmatic subjects inhaled allergen causes rapid bronchoconstriction, reaching a maximum at 15 minutes and improving over the following 45 minutes, a finding similar to the airway response observed in atopic asthmatic patients.'3 We have confirmed our previous observation that in atopic subjects oral terfenadine, a potent and selective H, histamine receptor antagonist, inhibits allergen induced bronchoconstriction by about 50%.'3 After terfenadine the initial rate of fall in FEV, with inhaled allergen was slower than that observed after placebo, reflecting the rapid release of histamine from activated mast cells in the bronchial mucosa.
Immunological activation of human lung mast cells generates substantial amounts of the bronchoconstrictor prostanoid prostaglandin (PG) D2,7 which could also contribute to allergen provoked bronchoconstriction in vivo. To determine the contribution of PGD2 and other bronchoconstrictor prostanoids to the immediate reaction, we investigated the effect of the cyclo-oxygenase inhibitor flurbiprofen. The published reports of the influence of cyclo-oxygenase inhibitors on the airways response to inhaled allergen are confusing.'20 Two studies'720 have shown that indomethacin partially attenuates the bronchoconstrictor response to allergen in patients with asthma. Fish et al,'6 however, were unable to show any effect of indomethacin (50 mg six hourly for 96 hours) on the allergen response in atopic asthma, while in atopic normal subjects the response was potentiated. At first sight these conflicting reports are difficult to explain. One possible reason is that, at the doses used, insufficient concentrations of drug were available at the surface of the airways to inhibit cyclo-oxygenase activity of mediator secreting cells effectively. In support of this, Kleeberger et al,2' studying antigen induced bronchoconstriction in dogs, found that indomethacin in an intravenous dose of 4 mg/kg was necessary to inhibit PGD2 release into the broncho-950 alveolar lumen after challenge. For this reason we chose flurbiprofen, which is more potent than aspirin or indomethacin in inhibiting microsomal cyclooxygenase by factors of 5000 and 20 times respectively." To ensure maximum inhibition of cyclooxygenase a dose regimen offlurbiprofen 150 mg daily for three days was chosen.
It was our initial intention to observe the effects of flurbiprofen on allergen provoked bronchoconstriction in patients with atopic asthma, but before undertaking this study we examined the effects of the drug on the airway response to histamine and methacholine. Despite having no effect on methacholine responsiveness, flurbiprofen had a significant inhibitory effect on the airways response to histamine, displacing the concentration-response curve to the right by more than one doubling concentration.
Walters et al reported that inhalation of PGF2, caused an increase in airway sensitivity to histamine22 and that therapeutic doses of indomethacin reduced airways reponsiveness to histamine in asthmatic subjects, leading them to suggest a contributory role for prostanoids in the constrictor airway response to this mediator. Platshon and Kaliner24 found that histamine is capable of releasing PGF2, from human lung tissue in vitro, and that a similar response was also mediated by a more specific H, agonist, 2-methyl histamine, and inhibited by an H, histamine receptor antagonist.
Thus part of the bronchoconstrictor effect of histamine in asthma could be mediated by endogenously released PGF2, removal of which by a cyclooxygenase inhibitor would be expected to reduce the airways response to histamine. Flurbiprofen is unlikely to have affected non-specific bronchial responsiveness directly since the drug had no effect on the airway response to methacholine, a muscarinic agonist that contracts airway smooth muscle directly. Other possible explanations for flurbiprofen's alteration of histamine responsiveness in asthma include inhibition of the reflex component of bronchoconstriction produced by histamine, down regulation of histamine H, receptors, and modulation of postreceptor events coupled to histamine mediated contraction of smooth muscle.
Whatever the mechanism responsible for flurbiprofen's effect on histamine responsiveness in asthma, its action precluded us from using asthmatic patients for dissecting the component of the allergen response attributable to prostanoids since endogenously released histamine causes at least 50% of the bronchoconstrictor response to allergen.'3 Walters et afl2 found that indomethacin had no effect on histamine responsiveness in atopic non-asthmatic subjects, unlike the asthmatic subjects; for this reason the major part of the study was conducted on atopic non-asthmatic subjects in whom the airways response to inhaled Curzen. Rafferty, Holgate histamine fell well outside the asthmatic range (> 32 mg/ml). We did not consider it ethical to administer histamine in concentrations of more than 32 mg/ml because of the risk of laryngeal oedema, so we were unable to confirm the observations of Walters et al. Pretreatment with flurbiprofen inhibited bronchoconstriction with inhaled allergen by about 30% over the first 60 minutes, covering the immediate response. As can be seen from the figure, flurbiprofen produced its maximum inhibitory effect between 7 and 25 minutes and this correlates well with time course of PGD2 release from immunologically activated lung mast cells in vitro with maximum release of PGD2 at 15 minutes.7
We have previously shown that a combination of histamine and PGD2, when administered by inhalation to subjects with asthma in equibronchoconstrictor concentrations, had purely additive effects.25 If these two mediators were released together from activated bronchial mast cells after allergen challenge, the combination of terfenadine and flurbiprofen might be expected to produce additive inhibition of allergen provoked bronchoconstriction. The figure, however, shows that the drug combination produced no greater protection of the airways against allergen than did terfenadine alone. To gain further insight into the contribution of histamine and prostanoids in allergen induced acute allergic reponses, we studied the effect of terfenadine and flurbiprofen alone and in combination on the Effects offlurbiprofen and terfenadine on allergen induced immediate bronchoconstriction immediate skin weal response to allergen. In a dose that almost completely inhibited the skin weal response to histamine, terfenadine inhibited the response to allergen by only 62%, implying that mediators other than histamine contribute to the allergen induced increase in postcapillary venule permeability. Flurbiprofen, on the other hand, produced a significant 36% potentiation of the weal response. This may be due to the capacity of flurbiprofen to remove an inhibitory prostaglandin, thereby increasing the vascular response to released histamine or enhancing mast cell degranulation. The former possibility is particularly attractive since the skin weal response to histamine was also enhanced, although in the small number ofsubjects studied this did not reach statistical significance. Another possible explanation is that cyclo-oxygenase blockade leads to an increase in the allergen provoked production of leukotrienes, which have also been shown to be highly potent in increasing vascular permeability. 3' In conclusion, the use of terfenadine, as a highly selective and specific antagonist of histamine at the H, receptor, has shown that in atopic normal subjects about half of the immediate allergen induced bronchoconstrictor response can be accounted for by mast cell derived histamine. On the basis of the known pharmacological specificity of flurbiprofen at therapeutic concentrations on the cyclo-oxygenase enzyme system, we conclude that prostaglandins contribute to the increased airways responsiveness to histamine in subjects with asthma and, at least in atopic non-asthmatic subjects, to allergen provoked immediate bronchoconstriction but not to the skin weal response. The combination of terfenadine and flurbiprofen in the airways and skin produce complex results, which could be interpreted as enhanced release of further agonist mediators or removal of inhibitory prostaglandins. The further definition of the potential role of inhibitor prostanoids in allergen induced bronchoconstriction will have to await the availability of specific prostanoid receptor antagonists.
